Exousia Bio, Inc. (LMMY) stock: key figures, P/E, revenue and dividend

Consumer Discretionary · United States

Price
0.01 USD
Market cap
635,250.00 USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Exousia Bio, Inc. financials

Fiscal year2025
Revenue3,750.00 USD
Gross profit-3,501.00 USD
EBIT51,395.00 USD
Net income51,395.00 USD
Diluted EPS – continuing operations0.00 USD

Full history since 2022, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Exousia Bio, Inc.

Exousia Bio, Inc., a biotechnology company, designs, develops, and manufactures mammalian- and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company's platform enables the custom production of exosomes with enhanced genetic functionality that can selectively target specific cells to address diseases. The company was formerly known as LAMY and changed its name to Exousia Bio, Inc. in January 2026. The company was incorporated in 2022 and is based in Saint Petersburg, Florida.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.